

| | | |
|--|------------------------|------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Attorney Docket Number | 4239-66912-02 |
| | Application Number | 10/530,254 |
| | Filing Date | April 4, 2005 |
| | First Named Inventor | Sternberg |
| | Art Unit | 1646 |
| | Examiner Name | Not Yet Assigned |

U.S. PATENT DOCUMENTS


Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|-----------|------------------|-------------------------------|
| /GC/ | | 5,846,711 | 12/08/1998 | Moore <i>et al.</i> |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|---------|--------|------------------|-------------------------------|
| | | | | | |

OTHER DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | |
|---|---------------------|---|
| /GC/ | | Written Opinion of the International Searching Authority, mailed September 28, 2005, for corresponding International Application No. PCT/US2003/0031406, 6 pages. |
|  | | European Patent Office, "Communication -European Search Report" for European Application No. EP03773114.8 - 2401, February 15, 2006, 5 pages. |
| | | S.H. Leppla, "The Comprehensive Sourcebook of Bacterial Protein Toxins," 3 rd edition, 323-347, 2006. |
| | | Webster, <i>et al.</i> , "Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo," <i>Mol. Cell. Endo.</i> , 241(1): 21-31, 2005. |

| | | | |
|---|----------------|------------------|------------|
| EXAMINER SIGNATURE: | /Gyan Chandra/ | DATE CONSIDERED: | 12/11/2007 |
| <p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | |



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | |
|------------------------|---------------------|
| Attorney Docket Number | 4239-66912-02 |
| Application Number | 10/530,254 |
| Filing Date | April 4, 2005 |
| First Named Inventor | Esther M. Sternberg |
| Art Unit | 1646 |
| Examiner Name | To be assigned |

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|-------------------|------------------|-------------------------------|
| /GCI/ | | 5,006,330 | 09 Apr 1991 | Sternberg <i>et al.</i> |
| /GCI/ | | 5,677,274 | 14 Oct 1997 | Leppla <i>et al.</i> |
| /GCI/ | | US2003/0207833 A1 | 06 Nov 2003 | Berkley <i>et al.</i> |
| | | | | |
| | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials* | Cite No. (optional) | Country | Number | Publication Date | Name of Applicant or Patentee |
|----------------------|---------------------|----------|-------------|------------------|---|
| /GCI/ | | WIPO/PCT | WO 98/26783 | 25 June 1998 | Hoechst Marion Roussel |
| | | WIPO/PCT | WO 98/27986 | 02 July 1998 | Zymogenetics, Inc. |
| | | WIPO/PCT | WO 99/50439 | 07 Oct 1999 | The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services |
| ↓ | | WIPO/PCT | WO 01/21656 | 29 Mar 2001 | The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services |
| | | | | | |
| | | | | | |
| | | | | | |

EXAMINER
SIGNATURE: /Gyan Chandra/

DATE
CONSIDERED: 12/11/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|---------------------|--|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Attorney Docket Number | 4239-66912-02 |
| | | Application Number | 10/530,254 |
| | | Filing Date | April 4, 2005 |
| | | First Named Inventor | Esther M. Sternberg |
| | | Art Unit | 1646 |
| | | Examiner Name | To be assigned |
| Examiner's Initials* | Cite No. (optional) | OTHER DOCUMENTS | |
| IGC/ | | ARORA <i>et al.</i> , "Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells," <i>The Journal of Biological Chemistry</i> 267(22):15542-15548, 1992 | |
| | | ARORA <i>et al.</i> , "Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides," <i>The Journal of Biological Chemistry</i> 268(5):3334-3341, 1993 | |
| | | ARORA <i>et al.</i> , "Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells," <i>Infection and Immunity</i> 62(11):4955-4961, 1994 | |
| | | ARORA <i>et al.</i> , "Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells," <i>The Journal of Biological Chemistry</i> 269(42):26165-26171, 1994 | |
| | | BHATNAGAR <i>et al.</i> , "Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1," <i>Infection and Immunity</i> 57(7):2107-2114, 1989 | |
| | | BHATNAGAR <i>et al.</i> , "Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity," <i>Infection and Immunity</i> 62(7):2958-2962, 1994 | |
| | | BHATNAGAR <i>et al.</i> , "Anthrax toxin," <i>Clinical Reviews in Microbiology</i> 27(3):167-200, 2001 | |
| | | BLEDSOE <i>et al.</i> , "Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition," <i>Cell</i> 110:93-105, 2002 | |
| | | BRADLEY <i>et al.</i> , "Identification of the cellular receptor for anthrax toxin," <i>Nature</i> 414:225-229, 2001 | |
| | | CASTAGLIUOLO <i>et al.</i> , "Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats," <i>Am J Physiol Gastrointest Liver Physiol</i> 280:G539-G545, 2001 | |
| | | CHAUDRY <i>et al.</i> , "Quickening the pace of anthrax research: three advances point towards possible therapies," <i>Trends in Microbiology</i> 10(2):58-62, 2002 | |
| | | DUESBERY <i>et al.</i> , "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor," <i>Science</i> 280:734-737, 1998 | |
| ↓ | | DUESBERY <i>et al.</i> , "Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase," <i>Journal of Applied Microbiology</i> 87:289-293, 1999 | |

EXAMINER
SIGNATURE:

/Gyan Chandra/

DATE

CONSIDERED:

12/11/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|--|---|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Attorney Docket Number | 4239-66912-02 |
| | | Application Number | 10/530,254 |
| | | Filing Date | April 4, 2005 |
| | | First Named Inventor | Esther M. Sternberg |
| | | Art Unit | 1646 |
| | | Examiner Name | To be assigned |
| /GCI/ | | DUESBERY <i>et al.</i> , "Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways," <i>Proc. Natl. Acad. Sci. USA</i> 98(7):4089-4094, 2001 | |
| | | EDWARDS <i>et al.</i> , "The pituitary gland is required for protection against lethal effects of <i>Salmonella typhimurium</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 88:2274-2277, 1991 | |
| | | ERWIN <i>et al.</i> , "Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to <i>Bacillus anthracis</i> lethal toxin," <i>Infection and Immunity</i> 69(2):1175-1177, 2001 | |
| | | EZZELL <i>et al.</i> , "Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of <i>Bacillus anthracis</i> toxin," <i>Infection and Immunity</i> 45(3):761-767, 1984 | |
| | | FRIEDLANDER, "Protein kinase C activation has dissimilar effects on sodium-coupled uptakes in renal proximal tubular cells in primary culture," <i>The Journal of Biological Chemistry</i> 261(16):7123-7126, 1986 | |
| | | FRIEDLANDER <i>et al.</i> , "Characterization of macrophage sensitivity and resistance to anthrax lethal toxin," <i>Infection and Immunity</i> 61(1):245-252, 1993 | |
| | | GLASS <i>et al.</i> , "Nuclear receptor coactivators," <i>Current Opinion in Cell Biology</i> 9:222-232, 1997 | |
| | | GODOWSKI <i>et al.</i> , "Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement," <i>Nature</i> 325(6102):365-368, 1987 (Abstract) | |
| | | GOMEZ <i>et al.</i> , "Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome," <i>Clin Exp Immunol</i> 131:217-224, 2003 | |
| | | HAMMOND <i>et al.</i> , "Lethal factor active-site mutations affect catalytic activity in vitro," <i>Infection and Immunity</i> 66(5):2374-2378, 1998 | |
| | | HANNA <i>et al.</i> , "Role of macrophage oxidative burst in the action of anthrax lethal toxin," <i>Molecular Medicine</i> 1(1):7-18, 1994 | |
| | | HANNA <i>et al.</i> , "Understanding <i>Bacillus anthracis</i> pathogenesis," <i>Trends in Microbiology</i> 7(5):180-182, 1999 | |
| | | HANNA, "Lethal toxin actions and their consequences," <i>Journal of Applied Microbiology</i> 87:285-287, 1999 | |
| | | HERRLICH, "Cross-talk between glucocorticoid receptor and AP-1," <i>Oncogene</i> 20:2465-2475, 2001 | |
| ↓ | | KARIN <i>et al.</i> , "AP-1--glucocorticoid receptor crosstalk taken to a higher level," <i>Journal of Endocrinology</i> 169:447-451, 2001 | |

| | | | |
|---|----------------|---------------------|------------|
| EXAMINER SIGNATURE: | /Gyan Chandra/ | DATE CONSIDERED: | 12/11/2007 |
| <p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | |

| | | | |
|--|--|--|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Attorney Docket Number | 4239-66912-02 |
| | | Application Number | 10/530,254 |
| | | Filing Date | April 4, 2005 |
| | | First Named Inventor | Esther M. Sternberg |
| | | Art Unit | 1646 |
| | | Examiner Name | To be assigned |
| /GCI/ | | KLEIN <i>et al.</i> , "Dual Nature of Resistance Mechanisms as Revealed by Studies of Anthrax Septicemia," <i>J. Bacteriol.</i> 85:1032-1038, 1963 | |
| | | KLIMPEL <i>et al.</i> , "Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin," <i>Proc. Natl. Acad. Sci. USA</i> 89:10277-10281, 1992 | |
| | | KLIMPEL <i>et al.</i> , "Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity," <i>Molecular Microbiology</i> 13(6):1093-1100, 1994 | |
| | | KOO <i>et al.</i> , "Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase," <i>PNAS</i> 99(5):3052-3057, 2002 | |
| | | KRSTIC <i>et al.</i> , "Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate," <i>Molecular and Cellular Biology</i> 17(7):3947-3954, 1997 | |
| | | LEPPLA, "Production and purification of anthrax toxin," <i>Methods in Enzymology</i> 165:103-116, 1 st ed., Academic Press, 1998 | |
| | | LEPPLA, "Anthrax Toxin," <i>Handbook of Experimental Pharmacology</i> , Vol. 145, Chapter 19, pp. 445-472, 2000 | |
| | | LITTLE <i>et al.</i> , "Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin," <i>Infection and Immunity</i> 58(6):1606-1613, 1990 | |
| | | LITTLE <i>et al.</i> , "Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies," <i>Microbiology</i> 142:707-715, 1996 | |
| | | LOPEZ <i>et al.</i> , "Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity," <i>The Journal of Biological Chemistry</i> 276(25):22177-22182, 2001 | |
| | | LUCIBELLO <i>et al.</i> , "Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB," <i>The EMBO Journal</i> 9(9):2827-2834, 1990 | |
| | | KAU <i>et al.</i> , "Calyculin A sensitive protein phosphatase is required for Bacillus anthracis lethal toxin induced cytotoxicity," <i>Current Microbiology</i> 44:106-111, 2002 | |
| | | MACPHEE <i>et al.</i> , "Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids," <i>J. Exp. Med.</i> 169:431-445, 1989 | |

| | | | |
|------------------------|----------------|---------------------|------------|
| EXAMINER SIGNATURE: | /Gyan Chandra/ | DATE CONSIDERED: | 12/11/2007 |
|------------------------|----------------|---------------------|------------|

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | |
|--|--|---|------------------------|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | Attorney Docket Number | 4239-66912-02 |
| | | | Application Number | 10/530,254 |
| | | | Filing Date | April 4, 2005 |
| | | | First Named Inventor | Esther M. Sternberg |
| | | | Art Unit | 1646 |
| | | | Examiner Name | To be assigned |
| /GC/ | | MCEWAN <i>et al.</i> , "Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF," <i>Proc. Natl. Acad. Sci. USA</i> 94:8485-8490, 1997 | | |
| | | MCKENNA <i>et al.</i> , "Minireview: nuclear receptor coactivators--an update," <i>Endocrinology</i> 143(7):2461-2465, 2002 | | |
| | | MIESFELD <i>et al.</i> , "Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA," <i>Cell</i> 46(3):389-399, 1986 (Abstract) | | |
| | | MIESFELD <i>et al.</i> , "Glucocorticoid receptor mutants that define a small region sufficient for enhancer activation," <i>Science</i> 236(4800):423-427, 1987 (Abstract) | | |
| | | NEECK <i>et al.</i> , "Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome," <i>Neuroendocrine Mechanisms in Rheumatic Disease</i> 26(4):989-1002, 2000 | | |
| | | PANNIFER <i>et al.</i> , "Crystal structure of the anthrax lethal factor," <i>Nature</i> 414:229-233, 2001 | | |
| | | PELLIZZARI <i>et al.</i> , "Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN γ -induced release of NO and TNF α ," <i>FEBS Letters</i> 462:199-204, 1999 | | |
| | | PELLIZZARI <i>et al.</i> , "Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages," <i>Int. J. Med. Microbiol.</i> 290:421-427, 2000 | | |
| | | PEZARD <i>et al.</i> , "Contribution of individual toxin components to virulence of Bacillus anthracis," <i>Infection and Immunity</i> 59(10):3472-3477, 1991 | | |
| | | PRICE <i>et al.</i> , "Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein," <i>Infection and Immunity</i> 69(7):4509-4515, 2001 | | |
| | | QUINN <i>et al.</i> , "Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis," <i>The Journal of Biological Chemistry</i> 266(30):20124-20130, 1991 | | |
| | | REICHARDT <i>et al.</i> , "Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock," <i>Molecular and Cellular Biology</i> 20(23):9009-9017, 2000 | | |
| | | ROBERTS <i>et al.</i> , "Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11," <i>Molecular Microbiology</i> 29(2):581-591, 1998 | | |
| ↓ | | ROBERTSON <i>et al.</i> , "Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis," <i>Gene</i> 44:71-78, 1986 | | |

| | | | |
|---|----------------|---------------------|------------|
| EXAMINER SIGNATURE: | /Gyan Chandra/ | DATE CONSIDERED: | 12/11/2007 |
| <p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | |
|------------------------|---------------------|
| Attorney Docket Number | 4239-66912-02 |
| Application Number | 10/530,254 |
| Filing Date | April 4, 2005 |
| First Named Inventor | Esther M. Sternberg |
| Art Unit | 1646 |
| Examiner Name | To be assigned |

| | | |
|------|--|---|
| /GC/ | | ROGATSKY <i>et al.</i> , "Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase," <i>Proc. Natl. Acad. Sci. USA</i> 95(5):2050-2055, 1998 |
| | | RUZEK <i>et al.</i> , "Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection," <i>The Journal of Immunology</i> 162:3527-3533, 1999 |
| | | SCHMITT <i>et al.</i> , "Bacterial toxins: friends or foes?" <i>Emerging Infectious Diseases</i> 5(2):224-234, 1999 |
| | | SCHÜLE <i>et al.</i> , "Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor," <i>Cell</i> 62:1217-1226, 1990 |
| | | SHANKS <i>et al.</i> , "Mouse strain differences in plasma corticosterone following uncontrollable footshock," <i>Pharmacology Biochemistry & Behavior</i> 36:515-519, 1990 |
| | | SHIN <i>et al.</i> , "Intracellular calcium antagonist protects cultured peritoneal macrophages against anthrax lethal toxin-induced cytotoxicity," <i>Cell Biology and Toxicology</i> 16:137-144, 2000 |
| | | SINGH <i>et al.</i> , "Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells," <i>The Journal of Biological Chemistry</i> 264(19):11099-11102, 1989 |
| | | SINGH <i>et al.</i> , "Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells," <i>Infection and Immunity</i> 67(4):1853-1859, 1999 |
| | | STERNBERG <i>et al.</i> , "Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats," <i>Proc. Natl. Acad. Sci. USA</i> 86:2374-2378, 1989 |
| | | TANG <i>et al.</i> , "Proteasome activity is required for anthrax lethal toxin to kill macrophages," <i>Infection and Immunity</i> 67(6):3055-3060, 1999 |
| | | VITALE <i>et al.</i> , "Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor," <i>Biochem. J.</i> 352:739-745, 2000 |
| | | WADE <i>et al.</i> , "Anthrax toxin components stimulate chemotaxis of human polymorphonuclear neutrophils," <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 179:159-162, 1985 |
| | | WATTERS <i>et al.</i> , "Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor," <i>Current Biology</i> 11:1503-1511, 2001 |
| | | WEBSTER <i>et al.</i> , "Neuroendocrine regulation of immunity," <i>Annu. Rev. Immunol.</i> 20:125-163, 2002 |
| ↓ | | WEBSTER <i>et al.</i> , "Anthrax lethal factor represses glucocorticoid and progesterone receptor activity," <i>PNAS</i> 100(10):5706-5711, 2003 |

EXAMINER
SIGNATURE:

/Gyan Chandra/

DATE

CONSIDERED:

12/11/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|--|---|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Attorney Docket Number | 4239-66912-02 |
| | | Application Number | 10/530,254 |
| | | Filing Date | April 4, 2005 |
| | | First Named Inventor | Esther M. Sternberg |
| | | Art Unit | 1646 |
| | | Examiner Name | To be assigned |
| /GC/ | | WELKOS <i>et al.</i> , "Differences in susceptibility of inbred mice to <i>Bacillus anthracis</i> ," <i>Infection and Immunity</i> 51(3):795-800, 1986 | |
| /GC/ | | ZUCKERMAN <i>et al.</i> , "In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis by <i>Rhodobacter sphaeroides</i> diphosphoryl lipid A is dependent on corticosterone induction," <i>Infection and Immunity</i> 60(7):2581-2587, 1992 | |

| | | | |
|---|----------------|---------------------|------------|
| EXAMINER SIGNATURE: | /Gyan Chandra/ | DATE CONSIDERED: | 12/11/2007 |
| <p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | |